Cellectar Biosciences, Inc. Logo

Cellectar Biosciences, Inc.

Clinical-stage biopharma developing targeted cancer treatments via a PDC platform.

CLRB | US

Overview

Corporate Details

ISIN(s):
US15117F8077
LEI:
Country:
United States of America
Address:
100 CAMPUS DRIVE, 7932 FLORHAM PARK

Description

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted cancer treatments. The company's core technology is a proprietary Phospholipid Drug Conjugate (PDC) platform that selectively delivers therapeutic payloads, such as radioisotopes and cytotoxins, to cancer cells by targeting lipid rafts in their plasma membranes. This approach is designed to maximize antitumor activity while minimizing off-target effects on healthy tissue. Cellectar's lead product candidate is iopofosine I 131, a first-in-class PDC that delivers the radioisotope iodine-131. It is being developed for the treatment of hematologic malignancies and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for Waldenstrom's Macroglobulinemia.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cellectar Biosciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cellectar Biosciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cellectar Biosciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Dermapharm Holding SE Logo
A manufacturer of patent-free branded pharmaceuticals and healthcare products.
Germany
DMP
Dermata Therapeutics, Inc. Logo
Medical dermatology company developing and commercializing OTC skin care products.
United States of America
DRMA
Design Therapeutics, Inc. Logo
Clinical-stage biopharma developing small molecule therapies for genetic diseases.
United States of America
DSGN
Deutsche Biotech Innovativ AG Logo
Develops therapeutics for serious diseases using innovative blood biomarkers.
Germany
DBI
DEVA HOLDİNG A.Ş. Logo
Develops, produces, and markets human medicines, APIs, and veterinary drugs globally.
Spain
DEVA
Devyser Diagnostics Logo
Develops DNA testing kits for hereditary diseases, oncology, and post-transplant monitoring.
Sweden
DVYSR
DexTech Medical AB Logo
Develops drug candidates for urological oncology, focusing on prostate cancer.
Sweden
DEX
DiaMedica Therapeutics Inc. Logo
Clinical-stage biopharma developing therapies for ischemic and vascular diseases.
United States of America
DMAC
Diamyd Medical AB (publ) Logo
A clinical-stage company developing precision therapies for autoimmune diabetes.
Sweden
DMYD
Diasorin Logo
A global leader in In Vitro Diagnostics for immunodiagnostics and molecular diagnostics.
Italy
DIA

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.